PMV Pharmaceuticals is a precision oncology company focused on discovering and developing small molecule, tumor-agnostic therapies targeting p53. Their lead product candidate, rezatapopt, is an orally available small molecule designed to correct misfolded p53 caused by the Y220C mutation, restoring wild-type function. The company is conducting the PYNNACLE Phase 1/2 clinical trial and plans to submit an NDA for platinum-resistant/refractory ovarian cancer with TP53 Y220C mutation in Q1 2027.
Q2 FY2026 — expected 2026-09-08
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-06 | 2025-12-31 | 0001193125-26-095014 | EDGAR | 87K words |
| 2025-03-03 | 2024-12-31 | 0000950170-25-030414 | EDGAR | 87K words |
| 2024-02-29 | 2023-12-31 | 0000950170-24-023062 | EDGAR | 85K words |
| 2023-03-01 | 2022-12-31 | 0000950170-23-005345 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0001564590-22-007860 | EDGAR | — |
| 2021-03-03 | 2020-12-31 | 0001564590-21-010578 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-14 | 2026-06-30 | 0001193125-26-350448 | EDGAR | 20K words |
| 2025-11-12 | 2025-09-30 | 0001193125-25-276003 | EDGAR | 21K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-104588 | EDGAR | 21K words |
| 2025-05-09 | 2025-03-31 | 0000950170-25-067513 | EDGAR | 19K words |
| 2024-11-07 | 2024-09-30 | 0000950170-24-122817 | EDGAR | 20K words |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093343 | EDGAR | 19K words |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056295 | EDGAR | 17K words |
| 2023-11-09 | 2023-09-30 | 0000950170-23-061551 | EDGAR | 19K words |
| 2023-08-09 | 2023-06-30 | 0000950170-23-040153 | EDGAR | 19K words |
| 2023-05-10 | 2023-03-31 | 0000950170-23-020100 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0000950170-22-022920 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-015767 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-02 | 0001193125-26-378838 | EDGAR | 1K words |
| 2026-08-31 | 0001193125-26-376723 | EDGAR | 1K words |
| 2026-08-14 | 0001193125-26-350445 | EDGAR | 2K words |
| 2026-03-06 | 0001193125-26-095094 | EDGAR | 2K words |
| 2025-11-12 | 0001193125-25-276000 | EDGAR | 2K words |
| 2025-09-10 | 0001193125-25-199857 | EDGAR | 5K words |
| 2025-08-07 | 0000950170-25-104587 | EDGAR | 2K words |
| 2025-06-09 | 0001193125-25-137497 | EDGAR | 1K words |
| 2025-05-09 | 0000950170-25-067511 | EDGAR | 2K words |
| 2025-03-03 | 0000950170-25-030407 | EDGAR | 3K words |
75 total filings indexed. 47 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001699382 |
| Ticker | PMVP |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.pmvpharma.com |
| Listed | 2020-09-25 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/PMVP (~200 tokens, structured JSON with cryptographic provenance)